TMS and theta-burst stimulation
Noninvasive brain stimulation for depression, and deep TMS for OCD.
Reality check: Established for depression; cleared for OCD with a specific device. Not established for autism, ADHD or tics.
DetailsRESEARCH & WHAT’S NEXT
What’s changing—without the hype.
We separate what’s available now from what’s being tested and what remains speculative. A forecast is not a fact, and we label which is which.
AVAILABLE NOW
Available now
In clinical use today for specific indications—check the exact product and evidence.
Accelerated, MRI-guided TMS (SAINT)
Compresses treatment into five days using imaging to target stimulation.
Reality check: FDA-cleared for depression in 2022; access is still limited and longer-term data are developing.
DetailsEsketamine
A rapid-acting medicine for treatment-resistant depression given in certified clinics.
Reality check: FDA-approved for specific depression indications; not the same as IV ketamine.
DetailsPrescription digital therapeutics
Software reviewed by FDA for a specific use, like EndeavorRx for attention in children with ADHD.
Reality check: Narrow indications and modest evidence so far; most wellness apps are not regulated treatments.
DetailsTelehealth specialty care
CBIT, ERP, CBT-I and psychiatry by video widen access to scarce specialists.
Reality check: Well established for many therapies; licensing rules mean the clinician usually must be licensed in your state.
BEING TESTED (NEXT FEW YEARS)
Being tested (next few years)
In active trials or early adoption. Promising, not proven.
AI-assisted care navigation and measurement
Tools that help organize symptoms, summarize records and prepare questions—like NeuroCoach’s Care Plan.
Reality check: Useful for organizing and preparing; should never diagnose or change treatment on their own.
Wearables and digital biomarkers
Phones and wearables that passively track sleep, movement, speech or tics.
Reality check: Active research; consumer measurements are not diagnoses.
Wearable neuromodulation for tics
Devices like Neupulse that stimulate a nerve at the wrist to reduce tics.
Reality check: Early trials; not routine care.
DetailsTranscranial focused ultrasound for psychiatric research
Researchers are exploring sound-wave approaches to influencing selected brain circuits without implanted electrodes.
Reality check: Experimental for psychiatric indications. A November 10, 2026 FDA-co-sponsored workshop discusses safety and study design; it is not a treatment clearance.
DetailsUltrasound and persistent delusions
A ten-person randomized pilot tested brain-circuit targeting in people with psychosis.
Reality check: Investigational: a preliminary delusion-score difference, but no confirmatory seven-day benefit or established longer-term safety.
DetailsAI brain imaging for schizophrenia
Researchers use radiomics models to analyze MRI patterns.
Reality check: A 14-study review shows potential, large between-study variation and limited external validation; not ready for clinical diagnosis.
DetailsBetter-targeted neuromodulation
Personalized targeting and closed-loop stimulation that adjusts in real time.
Reality check: A 2026 retrospective study linked specific DBS brain pathways with sustained improvement in 131 people with treatment-resistant depression. DBS for depression remains investigational; prospective efficacy and safety trials are needed.
DetailsLONGER HORIZON
Longer horizon
Plausible directions that need major breakthroughs first. Forecasts, not facts.
Brain-computer interfaces (BCIs)
Implanted devices, such as Neuralink’s, that let people with severe paralysis control computers with neural signals.
Reality check: Current implanted BCI research focuses on severe motor impairment. There is no established BCI treatment for autism, ADHD, OCD, Tourette syndrome, bipolar disorder or schizophrenia, and NeuroCoach won’t describe one as near-term without condition-specific evidence.
Precision psychiatry
Combining genetics, imaging and clinical data to predict which treatment fits whom.
Reality check: Promising research direction; few tools are ready for routine use yet.
Brain-computer interfaces: what they can—and can’t—do today
Brain-computer interfaces are an important area of neuroscience. Implanted systems, including Neuralink’s, are being studied primarily to let people with severe paralysis control computers and other devices using neural signals.
There is currently no established BCI treatment for autism, ADHD, OCD, Tourette syndrome, bipolar disorder or schizophrenia. The useful question isn’t “Will Neuralink cure autism?” but: what can today’s BCI research actually do, what problems is it solving, and what breakthroughs would be needed before psychiatric or neurodevelopmental uses became realistic?
Our rule: we won’t describe any implanted BCI as an established or near-term treatment for these conditions without condition-specific evidence and regulatory support.
Sources
Sources checked October 5, 2026. Links support this page; they don’t imply endorsement of NeuroCoach.
- Neuralink (company site) Neuralink
- Brain Stimulation Therapies NIMH
- FDA clears SAINT rapid-acting brain stimulation approach for treatment-resistant major depression Brain & Behavior Research Foundation (2022)
- De Novo decision summary: EndeavorRx FDA (2020)